Abstract
The objectives of this research were to evaluate the stability of parthenolide in feverfew solution state and powdered feverfew (solid state), and explore the compatibility between commonly used excipients and parthenolide in feverfew. Feverfew extract solution was diluted with different pH buffers to study the solution stability of parthenolide in feverfew. Powdered feverfew extract was stored under 40°C/0%∼75% relative humidities (RH) or 31% RH/5∼50°C to study the influence of temperature and relative humidity on the stability of parthenolide in feverfew solid state. Binary mixtures of feverfew powered extract and different excipients were stored at 50°C/ 75% RH for excipient compatibility evaluation. The degradation of parthenolide in feverfew solution appears to fit a typical first-order reaction. Parthenolide is comparatively stable when the environmental pH is in the range of 5 to 7, becoming unstable when pH is less than 3 or more than 7. Parthenolide degradation in feverfew in the solid state does not fit any obvious reaction model. Moisture content and temperature both play important roles affecting the degradation rate. A fter 6 months of storage, parthenolide in feverfew remains constant at 5°C/31% RH. However, ∼40% parthenolide in feverfew can be degraded if stored at 50°C/31% RH. When the moisture changed from 0% to 75% RH, the degradation of parthenolide in feverfew increased from 18% to 32% after 6-month storage under 40°C. Parthenolide in feverfew exhibits good compatibility with commonly used excipients under stressed conditions in a 3-week screening study.
Keywords: Feverfew, Botanical, Parthenolide, Stability, Excipient compatibility
Full Text
The Full Text of this article is available as a PDF (204.4 KB).
References
- 1.Kemper KJ. Feverfew (Tanacetum parthenium). Available at: http://www.longwoodherbal.org/feverfew/feverfew.pdf. Accessed November 2, 2007.
- 2.Abourashed EA, Khan IA, Abourashed EA, Khan IA. Determination of parthenolide in selected feverfew products by liquid chromatography. J AOAC Int. 2000;83:789–792. [PubMed] [Google Scholar]
- 3.Draves AH, Walker SE. Parthenolide content of Canadian commerical feverfew preparations: label claims are misleading in most cases. Can Pharm J. 2004;136:23–30. [Google Scholar]
- 4.Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. Am J Health Syst Pharm. 2002;59:1527–1531. doi: 10.1093/ajhp/59.16.1527. [DOI] [PubMed] [Google Scholar]
- 5.Jin P, Madieh S, Augsburger LL. Selected physical and chemical properties of feverfew (tanacetum parthenium) extracts important for formulated product quality and performance.AAPS PharmSciTech. In press. [DOI] [PMC free article] [PubMed]
- 6.Hendricks H, Anderson-Wildeboer Y, Engels G, Bos R, Woerdenbag H. The content of parthenolide and its yield per plant during the growth ofTanacetum parthenium. Plant Med. 1997;63:356–359. doi: 10.1055/s-2006-957700. [DOI] [PubMed] [Google Scholar]
- 7.Rushing JW, Hassell RL, Dufault RJ. Drying temperature and developmental stage at harvest influence the parthenolide content of feverfew leaves and stems. Acta Hort. 2004;629:167–173. [Google Scholar]
- 8.Kaplan M, Simmonds MR, Davidson G. Comparison of supercritical fluid and solvent extraction of feverfew (Tanacetum parthenium) Turk J Chem. 2002;26:473–480. [Google Scholar]
- 9.Tanko HM, Carrier DJ, Sokhansanj S, Crowe TG. Effects of drying temperature and storage on parthenolide concentration of feverfew (Tanacetum parthenium L.) leaves. Journal of Nutraceuticals, Functional and Medicinal Foods. 2003;4:27–37. doi: 10.1300/J133v04n01_04. [DOI] [Google Scholar]
- 10.Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol. 1992;44:391–395. doi: 10.1111/j.2042-7158.1992.tb03631.x. [DOI] [PubMed] [Google Scholar]
- 11.Smith RM, Burford MD. Supercritical fluid extraction and gas chromatographic determination of the sesquiterpene lacatone parthenolide in the medicinal herb feverfew. J Chromatog. 1992;627:255–261. doi: 10.1016/0021-9673(92)87205-M. [DOI] [Google Scholar]
- 12.Stability Testing of New Drug Substances and Products.ICH Expert Working Group. Available at: http://www.ich.org/LOB/media/MEDIA419.pdf. Accessed December 6, 2007.
- 13.Castaneda-Acosta J, Fischer NH, Vargas D. Biomimetic transformations of parthenolide. J Nat Prod. 1993;56:90–98. doi: 10.1021/np50091a013. [DOI] [PubMed] [Google Scholar]
- 14.Neukirch H, Kaneider NC, Wiedermann CJ, Guerriero A, D’Ambrosio M. Parthenolide and its photochemically synthesized 1(10) Z isomer: chemical reactivity and structure-activity relationship studies in human leucocyte chemotaxis. Bioorg Med Chem. 2003;11:1503–1510. doi: 10.1016/S0968-0896(02)00553-9. [DOI] [PubMed] [Google Scholar]
- 15.Kopelman SH, Augsburger LL. Excipient compatibility study ofHypericum perforatum extract (St. John’s wort) using similarity metrics to track phytochemical profile changes. Int J Pharm. 2002;237:35–46. doi: 10.1016/S0378-5173(02)00025-X. [DOI] [PubMed] [Google Scholar]
- 16.Serajuddin AT, Thakur AB, Ghoshal RN, et al. Selection of solid dosage form composition through drug-excipient compatibility testing. J Pharm Sci. 1999;88:696–704. doi: 10.1021/js980434g. [DOI] [PubMed] [Google Scholar]
- 17.Van Dooren AA, Duphar BV. Design for drug-excipient interaction studies. Drug Dev Ind Pharm. 1983;9:43–55. doi: 10.3109/03639048309048544. [DOI] [Google Scholar]
- 18.Patel N, Patel I, Cutie A, Wadke D, Monkhouse D, Reier G. The effect of selected direct compression excipients on the stability of aspirin as a model hydrolyzable drug. Drug Dev Ind Pharm. 1988;14:77–98. doi: 10.3109/03639048809151962. [DOI] [Google Scholar]